Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.

"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors are contract or full-time employees of Novavax and as such receive a salary for their work."

"Funding This work was supported by Novavax, Inc. and initially by the Coalition for Epidemic Preparedness Innovations (CEPI®)."

"The trial protocol was approved by the Alfred Hospital Ethics Committee (Melbourne, Victoria, Australia) and Advarra Central Institutional Review Board (Columbia, Maryland, USA) and is registered on Clinicaltrials.gov (NCT04368988). This study was performed in accordance with the International Council for Harmonisation, Good Clinical Practice guidelines. Safety oversight for the study was provided by an independent safety monitoring committee."